NCT03628612View on ClinicalTrials.gov

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

July 31, 2043

Study Completion Date

December 31, 2043

Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell TherapyMultiple MyelomaDLBCLALL, Adult and PediatricT Cell Lymphoma
Interventions
BIOLOGICAL

AUTO CAR T cell therapy

No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.

Trial Locations (8)

33136

University of Miami, Miami

63110

Washington University in St. Louis, St Louis

78704

St David's South Austin Medical Center, Austin

Unknown

Queen Elizabeth University Hospital, Glasgow

University College London Hospitals NHS Foundation Trust, London

Manchester Royal Infirmary Hospital, Manchester

Royal Manchester Children's Hospital, Manchester

Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
lead

Autolus Limited

INDUSTRY